http://www.theaustralian.news.com.au/story/0,25197,23275761-643,00.htmlLooks like Sapex is in the right place at the right time with the right partners.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%